Overview

• Novo Nordisk reports record profits led by the US demand for weight loss drugs, Wegovy and Ozempic, amid global shortages and concerns over a black market for counterfeit versions.
• With rising global shortages, a black market trade for the popular weight-loss drugs is thriving, leading to a surge in counterfeit products, endangering consumers and leading to hospitalizations over adverse reactions to fake drugs.
• Novo Nordisk is grappling with production constraints due to higher-than-expected demand for its blockbuster weight-loss drugs highlighting an increasingly lucrative yet dangerously unregulated black market.
• Pharmaceutical companies Novo Nordisk and Eli Lilly see record sales increase due to skyrocketing prescriptions for weight-loss and diabetes drugs, specifically Novo Nordisk's Ozempic and Wegovy.
• Weight-loss drug Wegovy continues to experience supply shortages despite soaring demand and record profits, affecting the availability of the drug for new patients, particularly in the US.